CGEN COMPUGEN LTD Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1119774 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY161.1%
TTM net income YoY348.4%
TTM EPS YoY337.5%
Revenue 3-yr CAGR113.3%
Net income 3-yr CAGR—
Margins
Gross margin87.3%
Operating margin43.1%
Net margin48.6%
FCF margin43.1%
EBITDA margin43.7%
Returns
ROE44.8%
ROA26.0%
ROIC (approx.)128.1%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio6.56x
Interest coverage1,118.79x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio2.7%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $72.76M | $27.86M |
| Cost of revenue | $9.25M | $7.93M |
| Gross profit | $63.51M | $19.93M |
| R&D expense | $22.76M | $24.81M |
| SG&A expense | $8.89M | $9.44M |
| Operating income | $31.33M | -$14.89M |
| Interest expense | $28,000 | $34,000 |
| Pretax income | $35.40M | -$9.71M |
| Income tax | $54,000 | $4.52M |
| Net income | $35.34M | -$14.23M |
| EBITDA | $31.80M | -$14.40M |
| EPS (basic) | 0.38 | -0.16 |
| EPS (diluted) | 0.38 | -0.16 |
| Weighted avg. shares (diluted) | 93.82M | 89.53M |
| Balance sheet | ||
| Cash & equivalents | $90.60M | $18.23M |
| Short-term investments | $9.28M | $23.63M |
| Receivables | — | $0 |
| Current assets | $148.02M | $106.00M |
| PP&E, net | $681,000 | $852,000 |
| Total assets | $156.57M | $115.00M |
| Current liabilities | $22.57M | $20.16M |
| Total liabilities | $53.84M | $60.08M |
| Shareholders' equity | $102.73M | $54.91M |
| Shares outstanding | 94.55M | 89.54M |
| Cash flow statement | ||
| Operating cash flow | $31.63M | $49.60M |
| Capital expenditure | $306,000 | $118,000 |
| Free cash flow | $31.33M | $49.49M |
| Investing cash flow | $30.00M | -$46.25M |
| Financing cash flow | $10.60M | $554,000 |
| Depreciation & amortization | $475,000 | $486,000 |
| Stock-based compensation | $1.88M | $3.02M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.